1. Curcumin-1,2,3-Triazole Conjugation for Targeting the Cancer Apoptosis Machinery.
- Author
-
Seghetti F, Di Martino RMC, Catanzaro E, Bisi A, Gobbi S, Rampa A, Canonico B, Montanari M, Krysko DV, Papa S, Fimognari C, and Belluti F
- Subjects
- Antineoplastic Agents chemistry, Cell Proliferation, Curcumin chemistry, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Humans, Leukemia, T-Cell drug therapy, Molecular Structure, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Structure-Activity Relationship, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Apoptosis, Curcumin pharmacology, Leukemia, T-Cell pathology, Membrane Potential, Mitochondrial drug effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Triazoles chemistry
- Abstract
The burden of neoplastic diseases is widely recognized as a severe cause of mortality. The clinical inadequacy of most anticancer therapeutics urgently prompted intense drug discovery efforts toward the identification of new chemical entities endowed with a potent and safe antitumor profile. In this scenario, targeting cancer cells apoptosis machinery has emerged as a relevant strategy, useful for tackling the emergence of drug resistance. On this basis, a small library of naturally inspired hybrid molecules was obtained by combining, through a click chemistry approach, "privileged" synthons such as curcumin scaffold and 1,2,3-triazole building block. Compound 1 , bearing a para -fluoro phenyl moiety, showed low-micromolar potency against T acute lymphoblastic leukemia cell growth. More in-depth biologic studies demonstrated, for this analog, cell death-inducing properties associated with its capability to simultaneously activate both the receptor and the mitochondrial apoptosis cascades. This peculiar behavior offers promises for achieving an expanded anticancer effect, namely intense cytotoxic response coupled with reduced predisposition of chemoresistance insurgence. Altogether, this study allowed the identification of compound 1 as a lead compound worth to be progressed as an anticancer drug candidate.
- Published
- 2020
- Full Text
- View/download PDF